Trial Profile
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of 6R-BH4 in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapropterin (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- 14 Oct 2013 New trial record